---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269624"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:59:04.834725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026

## Summary
- Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.
- Cash, equivalents and marketable securities $383.9M as of Sep 30, 2025; runway into 2028 after $150M private placement.
- MZE782 Phase 1 positive: well-tolerated, dose-dependent urinary Phe and glutamine increase; eGFR dip observed.
- MZE782 Phase 2 trials in PKU and CKD expected to initiate in 2026; MZE829 HORIZON topline data by Q1 2026.
- Appointed Hervé Hoppenot as chairman and Misbah Tahir as CFO in Sep/Oct 2025.

## SEC filing metadata
- accession: 0001193125-25-269624
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/0001193125-25-269624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312525269624/maze-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269624
- JSON: https://secwatch.observer/filing/0001193125-25-269624.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.